THE VANDERBILT REPORT | ARTL
THE VANDERBILT REPORT
EQUITY RESEARCH & INVESTOR INTELLIGENCE
NASDAQ: ARTL | SEPTEMBER 2026 | CLINICAL-STAGE PHARMACEUTICALS
Artelo Biosciences: One Molecule, Three Jobs
Why ART27.13 Is Worth Understanding Before the Market Prices It
A clinical-stage cannabinoid pharmaceutical company with a peripherally selective drug candidate that gained weight in cancer patients, lost weight in obese mice, and did neither in lean ones — and what that combination might be worth.
AT A GLANCE
40% WEIGHT LOSS — ART27.13 + SEMAGLUTIDE COMBO (MOUSE MODEL) | 2041 PATENT PROTECTION RUNWAY — US, EU, JAPAN | +6% WEIGHT GAIN VS. −5% PLACEBO — CARES PHASE 2 INTERIM (HUMAN) | 300+ PARTICIPANTS ACROSS ART27.13'S PRIOR CLINICAL STUDIES |
Weight-loss figures are nonclinical (mouse model) and have not been tested in humans; CAReS figures are interim, small-n Phase 2 human data. See disclosures at the end of this report.
THE ONE-PARAGRAPH THESIS
Artelo Biosciences owns full global rights to a drug that pushes body weight in whichever direction the patient needs — up in cancer patients with cachexia, down in obese mice, unchanged in lean ones. That's not a simple appetite switch. It's the kind of signal that gets pharmaceutical business-development teams paying closer attention. The same molecule is already dosing patients in a funded human glaucoma study. Artelo is a lean, seven-person company with a sub-$3 million market cap sitting on a multi-indication clinical asset and a freshly reinforced balance sheet. The obesity data is early and nonclinical — and worth understanding before the market catches up.
TEACHING THE SCIENCE: WHY AN AGONIST ISN'T THE OLD CANNABINOID STORY
Cannabinoid drug development has a bad reputation with investors, and it's earned. The first wave of CB1-targeted drugs in the 2000s blocked the receptor system-wide — rimonabant, the best-known example, produced real weight loss and was pulled from European markets after being linked to depression and suicidal ideation. That history is why "CB1" still makes biotech investors flinch.
ART27.13 breaks that pattern. For more than two decades, the industry's approach to CB1 and body weight has run one direction: block the receptor. Full agonists — molecules that activate rather than shut it down — have largely been avoided, in part because of rimonabant's legacy. ART27.13 is a potent agonist of both CB1 and CB2, engineered to act in peripheral tissue while minimizing brain exposure — the design choice that sidesteps rimonabant's psychiatric liability. Producing meaningful weight and fat loss in obese animals through that mechanism is, by the Company's own account, a genuinely differentiated result in the field — not an incremental tweak on the old approach.
Researchers describe this as a "state-dependent metabolic regulator" — a compound that nudges weight in different directions depending on the body's starting state. That's the scientific thread connecting Artelo's three programs. It's a hypothesis, not a settled fact. But it's the reason a company this small has three legitimate clinical stories running at once instead of one.
THREE JOBS FOR ONE MOLECULE
1. Cancer anorexia-cachexia (the human data). This is where ART27.13 has actual clinical evidence in patients. In the Phase 2 CAReS trial, patients treated at the 1,300 µg dose for 12 weeks gained an average of 6.38% body weight, against a 5.42% loss in the placebo arm — a roughly 12-point swing on a condition with no FDA-approved pharmacological treatment. The dataset is small and interim, and it still needs to be replicated at scale. But it's real human data, not a model.
2. Obesity and GLP-1 combination potential (nonclinical — mouse data, not human data). The Company's DIO-2 study replicates and extends an earlier DIO-1 pilot, using the diet-induced obesity model that's the industry standard for evaluating GLP-1 drugs. Obese mice spent 15 weeks on a high-fat diet before treatment began, matched to the same strain as the lean controls to rule out genetics as a confound. ART27.13 monotherapy cut body weight by roughly 20% over four weeks — matching semaglutide's curve, with no statistically significant difference between the two. Combined, the pairing produced roughly 40% weight loss: double either agent alone, and a result the Company reports was statistically distinct from semaglutide alone, not just numerically larger.
Source: Artelo Biosciences, non-clinical DIO study data on file, Sept. 2026.
The full 28-day course behind that number tells the same story, week by week:
Body weight change by treatment arm, DIO-2 study (28-day). SC = standard chow (lean); HFD = high-fat diet (obese). Source: Artelo Biosciences, data on file, Sept. 2026.
The combination arm didn't just lose more weight — it landed at the body weight of the lean, healthy control animals, erasing the obesity phenotype in four weeks. The type of weight lost mattered just as much: roughly 80% of the weight lost on ART27.13, alone or combined, was fat mass, versus roughly 70% for semaglutide alone. The combination group's body composition normalized furthest toward the lean-control ratio of any arm in the study.
Source: Artelo Biosciences, non-clinical DIO study data on file, Sept. 2026.
Looked at simply as fat lost versus lean mass lost, the split is starker still: